ExoCoBio Expands Reach into Global Beauty Market with BENEV Acquisition

ExoCoBio, the forefront of exosome-based regenerative aesthetics, is proud to announce that they have taken a majority stake in BENEV, one of the world’s most renowned medical aesthetics companies. With this move, ExoCoBio broadens their reach and increases their ability to innovate and offer state-of-the-art aesthetic solutions to people around the globe.

For nearly two decades, BENEV has been leading the way in the medical aesthetics industry, introducing ground-breaking treatments and products to market. From their initial launch of the world’s first growth factor-based skincare products to their award-winning RF microneedling system and best-in-class PDO threads, BENEV has been at the forefront of innovation.

Most recently, they have developed an Exosome Regenerative Complex developed in collaboration with ExoCoBio – bringing cutting-edge treatments to clients around the globe.

BENEV’s award-winning “Regenerative Trifecta” has catapulted the company to become one of the fastest-growing businesses in the United States aesthetic medical market. Over the past three fiscal years, BENEV’s total revenue has grown at a whopping 117% CAGR, establishing them at the forefront of the industry.

ExoCoBio is revolutionizing the way we look at aesthetic and medical regeneration, thanks to its world-leading exosome products, ASCE+™ and ERC™. With 54 patents and 15 scientific publications, its products have been a hit since they were launched in 2019, with more than 3.5 million cases sold. ExoCoBio is paving the way for a new era of age-reversal and regenerative medicine, with the help of its cutting-edge exosome products.

At the Aesthetic and Anti-aging Medicine World Congress (AMWC) in March 2023, the ASCE+™ and ERC™ product line was awarded the prestigious title of “The Best Cosmetics” out of the world-renowned global anti-aging congress. It is a great honor to be recognized on the global stage for excellence in the cosmetics industry.

Exosomes have rapidly become one of the most sought-after components in the world of biotechnology, as their immense potential continues to be realized. From illuminating the role of disease-related cellular signals to being utilized as targeted drug delivery systems, exosomes provide a wealth of opportunity to further research and development in the ever-evolving field of biotechnology.

Exosomes are incredible and versatile messengers that play a pivotal role in regulating cellular communication. These microscopic vesicles, ranging in size from 30 to 200 nanometers, are the hidden gems of intercellular dialogues and act as checkpoints for altering both local and afar environments.

As such, they are gaining traction in areas of diagnostics, therapeutics and even cosmetics due to their remarkable ability to direct active components to their exact desired targets. Put simply, these mini marvels may just decide the future of our health.

ExoCoBio is delighted to have acquired BENEV, which will accelerate its expansion and growth. The addition advances ExoCoBio’s mission to establish a path between exosome science and clinical application, boosting exosome technology as a major trend in the market. According to CEO/CTO Byong Cho, this acquisition is integral to achieving the company’s goal.

We are delighted to announce that BENEV will be joining forces with ExoCoBio through the latter’s acquisition of the former. This strategic and financial partnership of the past six years, beginning with the U.S. launch of Exosome Regenerative Complex, will propel the company into the global medical aesthetic market with unparalleled strength.

Our expertise and brand, in combination with ExoCoBio’s cutting-edge science, technology, funding, and products, create a synergy for further success. Ethan Min, CEO of BENEV, expresses his appreciation for this opportunity.

About ExoCoBio Inc.

ExoCoBio, the world’s leading innovator in exosome-based regenerative aesthetics and medicine, has changed the game in the beauty industry since its 2017 launch. They are amongst the top 3 exosome-biotech companies, having developed ASCE+™ and ERC™, the first and best exosome-based aesthetic products powering the world’s only exosome skin booster industry.

About BENEV Company Inc.

Since 2000, BENEV has been a leader in the medical aesthetic industry, creating products and solutions designed to bring health, longevity, and beauty to the lives of their customers. The California-based, FDA-registered drug manufacturer provides a vast selection of innovative topical solutions, exosome products, PDO threads, and radiofrequency microneedling devices for skin and hair care, both domestically and internationally.

From manufacturing to research and development, sales, and marketing, BENEV has a fully-integrated business model, upholds an emphasis on their promise of providing the highest quality products.

Leave a Comment